Chaurand Jorge, Godínez-Victoria Marycarmen, Tellez-Girón Aldo, Facio-Umaña Jose-Alfredo, Jimenez-Ponce Fiacro
Maxillofacial Surgery Department, National Medical Center "20 de Noviembre" Institute for Social Security and Services for State Workers.
Research Department, Superior School of Medicine, National Polytechnic Institute.
J Oral Sci. 2020 Dec 23;63(1):37-40. doi: 10.2334/josnusd.20-0090. Epub 2020 Dec 9.
This study assessed the effectiveness of incobotulinum toxin type A (IBTx) for chronic myofascial pain affecting the masseter and temporal muscles.
Twenty two patients who received a diagnosis of chronic masseter and temporalis myofascial pain were evaluated by using a visual analog pain scale (VAS), digital pressure algometry, and the SF-36 Health Survey at baseline (T0), before IBTx injection. Patients were again evaluated at 2 months (T1) and 7 months (T2) after IBTx injection.
VAS scores for pain significantly differed (P = 0.029, Friedman test). Post-hoc tests showed a significant reduction in pain at 2 months (T0-T1) and 7 months (T0-T2) (P = 0.011 and P = 0.028, respectively; Wilcoxon test) but not between 2 and 7 months (P = 0.676; Wilcoxon test). There was no significant difference in pressure algometry values (P = 0.385, Friedman test). Quality of life (QOL) assessment showed a significant difference (P = 0.002, Friedman test). Post-hoc tests showed a significant improvement in QOLat 2 months, but no significant difference at 7 months (P = 0.004 and P = 0.260, Wilcoxon test).
IBTx injection resulted in safe, effective short-term pain relief for patients with chronic facial pain affecting the masseter and temporalis muscles.
本研究评估了A型肉毒杆菌毒素（IBTx）对影响咬肌和颞肌的慢性肌筋膜疼痛的疗效。
22例被诊断为慢性咬肌和颞肌肌筋膜疼痛的患者在注射IBTx前的基线期（T0），通过视觉模拟疼痛量表（VAS）、数字压力痛觉测量法和SF-36健康调查进行评估。在注射IBTx后的2个月（T1）和7个月（T2）再次对患者进行评估。
疼痛的VAS评分有显著差异（P = 0.029，Friedman检验）。事后检验显示在2个月（T0-T1）和7个月（T0-T2）时疼痛显著减轻（分别为P = 0.011和P = 0.028；Wilcoxon检验），但在2个月至7个月之间无显著差异（P = 0.676；Wilcoxon检验）。压力痛觉测量值无显著差异（P = 0.385，Friedman检验）。生活质量（QOL）评估显示有显著差异（P = 0.002，Friedman检验）。事后检验显示在2个月时QOL有显著改善，但在7个月时无显著差异（P = 0.004和P = 0.260，Wilcoxon检验）。
对于患有影响咬肌和颞肌的慢性面部疼痛的患者，注射IBTx可带来安全、有效的短期疼痛缓解。
